McKesson (MCK) stock has drawn fresh attention after recent trading, with the share price around $754.40 and returns down over the past month and past 3 months. This has prompted investors to reassess the healthcare distributor.
See our latest analysis for McKesson.
The recent weakness in McKesson’s share price, including a 1-day share price return of down 1.52% and a 90-day share price return of down 21.68%, sits against a much stronger long run. The 3-year total shareholder return is 99.08% and the 5-year total shareholder return is 303.60%, suggesting momentum has cooled even though longer term holders have still seen substantial value creation.
If McKesson’s recent pullback has you rethinking where growth in healthcare might come from next, it could be a good moment to look at 34 healthcare AI stocks
So with McKesson’s share price cooling after a strong multi year run, is the recent pullback giving you a chance to buy a global healthcare distributor at a discount, or is the market already pricing in future growth?
Most Popular Narrative: 20.7% Undervalued
Compared with the latest close at $754.40, the most followed narrative places McKesson’s fair value at $951.73, using a 7.11% discount rate to bring future cash flows back to today.
Increasing adoption of specialty and oncology pharmaceuticals, alongside recent acquisitions (Core Ventures and PRISM Vision) that expand the provider network and service portfolio, are improving revenue mix quality and positioning the company for higher operating margins and earnings growth.
Want to see what sits behind that earnings and margin story? The narrative leans heavily on projected revenue growth, stable profitability, and a richer business mix. The exact assumptions may surprise you.
Result: Fair Value of $951.73 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to weigh the risk of tighter drug pricing pressure and ongoing vertical integration, which could squeeze margins and reduce the role of wholesalers.
Find out about the key risks to this McKesson narrative.
Another View: What Does The P/E Ratio Say?
Analysts see upside for McKesson, yet the current P/E of 19x sits below the US Healthcare industry at 24.1x, the peer average at 21.2x, and the fair ratio estimate of 28.2x. That gap may point to a margin of safety or to a market that is cautious, so which interpretation do you find more convincing?
See what the numbers indicate about this valuation in our detailed comparison, See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out McKesson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals on value and sentiment, it can be helpful to act quickly and review the full picture for yourself by weighing up the 5 key rewards and 1 important warning sign
Looking for more investment ideas?
If you stop with just one stock, you could miss opportunities that fit your goals even better, so widen your search with a few focused stock shortlists.
- Target potential mispricings by scanning for companies that combine quality fundamentals with attractive pricing using the 46 high quality undervalued stocks.
- Strengthen the income side of your portfolio by reviewing the 10 dividend fortresses and see which payouts stand out for consistency and yield.
- Prioritise resilience by checking the 65 resilient stocks with low risk scores to find stocks that aim to balance growth potential with measured risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com